Display options
Cite
Han B, Liu W, Du J, et al. 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial. Vaccines (Basel). 2021;9(12)doi: 10.3390/vaccines9121407.
Han, B., Liu, W., Du, J., Liu, H., Zhao, T., Yang, S., Wang, S., Zhang, S., Liu, B., Liu, Y., & Cui, F. (2021). 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial. Vaccines, 9(12), . https://doi.org/10.3390/vaccines9121407
Han, Bingfeng, et al. "12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial." Vaccines vol. 9,12 (2021). doi: https://doi.org/10.3390/vaccines9121407
Han B, Liu W, Du J, Liu H, Zhao T, Yang S, Wang S, Zhang S, Liu B, Liu Y, Cui F. 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial. Vaccines (Basel). 2021 Nov 29;9(12). doi: 10.3390/vaccines9121407. PMID: 34960153; PMCID: PMC8705985.
Copy Download .nbib Format: NLM
Share it on

Vaccines (Basel). 2021 Nov 29;9(12). doi: 10.3390/vaccines9121407.

12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial.

Vaccines

Bingfeng Han, Wu Liu, Juan Du, Hanyu Liu, Tianshuo Zhao, Shubo Yang, Shuai Wang, Sihui Zhang, Bei Liu, Yaqiong Liu, Fuqiang Cui

Affiliations

  1. Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.
  2. Jingyuan County Center for Disease Control and Prevention, Baiyin 730600, China.
  3. Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China.
  4. Department of Infectious Diseases and Clinical Microbiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.

PMID: 34960153 PMCID: PMC8705985 DOI: 10.3390/vaccines9121407

Abstract

BACKGROUND: In initial studies, the immunogenicity and safety of hepatitis B vaccines in patients with diabetes has been assessed in China.

METHODS: In six township health centers in Gansu Province, 232 diabetic patients and 77 healthy people were allocated to receive two 3-dose hepatitis B vaccines (Group D20SC 0-1-6; Group D20CHO 0-1-6; Group ND20SC 0-1-6). Participants were followed up at 12 months after being fully vaccinated. One dose of the vaccine was randomly administered to non-responders. Chi-square test was used to compare the differences in response rate between two groups.

RESULTS: The anti-HBs response rates of three groups decreased from 84.1%, 89.1% and 88.3% at one month to 64.6%, 79.8% and 71.4% at twelve months. There was no statistical difference in the immune response rates between Group D20SC 0-1-6 and Group ND20SC 0-1-6; however, that of Group D20CHO 0-1-6 was higher than that of Group D20SC 0-1-6. After revaccination, the geometric mean concentrations were 491.7 mIU/mL and 29.7 mIU/mL after using vaccines containing 60 μg and 20 μg HBsAg.

CONCLUSIONS: At 12 months, immune response in diabetic patients were not significantly different from that in healthy people. Revaccination with one dose of hepatitis B vaccine containing 60 μg HBsAg for non-responders was more satisfactory.

Keywords: diabetes mellitus; hepatitis B vaccines; persistent immunogenicity; revaccination; vaccination

References

  1. Emerg Infect Dis. 2017 May;23(5):765-772 - PubMed
  2. Hum Vaccin Immunother. 2019;15(5):1171-1176 - PubMed
  3. Hepatology. 2005 Jun;41(6):1383-90 - PubMed
  4. J Med Virol. 2017 Mar;89(3):450-457 - PubMed
  5. Vaccines (Basel). 2021 Apr 01;9(4): - PubMed
  6. Zhonghua Yu Fang Yi Xue Za Zhi. 2010 Oct;44(10):918-22 - PubMed
  7. Infection. 2010 Oct;38(5):395-400 - PubMed
  8. Hum Vaccin Immunother. 2016 Mar 3;12(3):773-8 - PubMed
  9. Int J Med Sci. 2011;8(4):321-31 - PubMed
  10. Hum Vaccin Immunother. 2015;11(11):2716-22 - PubMed
  11. J Infect. 1986 Jul;13 Suppl A:39-45 - PubMed
  12. Am J Med. 1989 Sep 4;87(3A):14S-20S - PubMed
  13. Intern Med. 2019 Aug 15;58(16):2349-2355 - PubMed
  14. Vaccine. 2015 Jan 3;33(2):294-7 - PubMed
  15. Hum Vaccin Immunother. 2017 Jun 3;13(6):1-7 - PubMed
  16. Vaccine. 2011 May 17;29(22):3905-8 - PubMed
  17. Vaccine. 2012 Mar 9;30(12):2051-3 - PubMed
  18. BMC Infect Dis. 2019 Sep 18;19(1):811 - PubMed
  19. Zhonghua Yu Fang Yi Xue Za Zhi. 2016 Jun;50(6):484-90 - PubMed
  20. Vaccine. 1994 May;12(6):532-4 - PubMed
  21. J Diabetes Sci Technol. 2012 Jul 01;6(4):858-66 - PubMed
  22. Zhonghua Liu Xing Bing Xue Za Zhi. 2012 Sep;33(9):988-9 - PubMed
  23. J Clin Transl Hepatol. 2017 Dec 28;5(4):297-318 - PubMed
  24. Vaccine. 2021 Jun 8;39(25):3365-3371 - PubMed
  25. Sci Rep. 2016 Jun 21;6:27251 - PubMed
  26. Vaccine. 2011 Aug 26;29(37):6276-82 - PubMed
  27. Zhonghua Yu Fang Yi Xue Za Zhi. 2018 Jul 6;52(7):748-752 - PubMed
  28. Bull World Health Organ. 2019 Mar 1;97(3):230-238 - PubMed
  29. JAMA Netw Open. 2021 Aug 2;4(8):e2120929 - PubMed
  30. Hum Vaccin Immunother. 2020 Mar 3;16(3):687-692 - PubMed
  31. Diabetologia. 2018 Jun;61(6):1249-1260 - PubMed
  32. J Exp Med. 1991 Mar 1;173(3):531-8 - PubMed
  33. Clin Infect Dis. 2002 Dec 1;35(11):1368-75 - PubMed
  34. Vaccine. 2019 Jan 7;37(2):223-225 - PubMed
  35. BMC Pediatr. 2017 Jul 14;17(1):164 - PubMed
  36. Vaccine. 2009 Nov 5;27(47):6550-7 - PubMed
  37. Vaccine. 2014 Jun 17;32(29):3706-12 - PubMed
  38. Immunol Res. 2016 Feb;64(1):242-50 - PubMed

Publication Types

Grant support